Imidazoline Receptor System: The Past, the Present, and the Future

咪唑啉受体 胍丁胺 莫索尼定 利门尼丁 可乐定 受体 兴奋剂 化学 药理学 变构调节 立体化学 生物化学 内分泌学 医学 氨基酸 精氨酸
作者
Pascal Bousquet,Alan L. Hudson,Jesús A. García‐Sevilla,Jun‐Xu Li
出处
期刊:Pharmacological Reviews [American Society for Pharmacology and Experimental Therapeutics]
卷期号:72 (1): 50-79 被引量:100
标识
DOI:10.1124/pr.118.016311
摘要

Imidazoline receptors historically referred to a family of nonadrenergic binding sites that recognize compounds with an imidazoline moiety, although this has proven to be an oversimplification. For example, none of the proposed endogenous ligands for imidazoline receptors contain an imidazoline moiety but they are diverse in their chemical structure. Three receptor subtypes (I1, I2, and I3) have been proposed and the understanding of each has seen differing progress over the decades. I1 receptors partially mediate the central hypotensive effects of clonidine-like drugs. Moxonidine and rilmenidine have better therapeutic profiles (fewer side effects) than clonidine as antihypertensive drugs, thought to be due to their higher I1/α2-adrenoceptor selectivity. Newer I1 receptor agonists such as LNP599 [3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine hydrochloride] have little to no activity on α2-adrenoceptors and demonstrate promising therapeutic potential for hypertension and metabolic syndrome. I2 receptors associate with several distinct proteins, but the identities of these proteins remain elusive. I2 receptor agonists have demonstrated various centrally mediated effects including antinociception and neuroprotection. A new I2 receptor agonist, CR4056 [2-phenyl-6-(1H-imidazol-1yl) quinazoline], demonstrated clear analgesic activity in a recently completed phase II clinical trial and holds great promise as a novel I2 receptor–based first-in-class nonopioid analgesic. The understanding of I3 receptors is relatively limited. Existing data suggest that I3 receptors may represent a binding site at the Kir6.2-subtype ATP-sensitive potassium channels in pancreatic β-cells and may be involved in insulin secretion. Despite the elusive nature of their molecular identities, recent progress on drug discovery targeting imidazoline receptors (I1 and I2) demonstrates the exciting potential of these compounds to elicit neuroprotection and to treat various disorders such as hypertension, metabolic syndrome, and chronic pain.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LL关闭了LL文献求助
刚刚
56jhjl完成签到,获得积分10
刚刚
1秒前
2秒前
123完成签到,获得积分10
4秒前
gaodadeni发布了新的文献求助10
4秒前
6秒前
核桃发布了新的文献求助10
6秒前
7秒前
wakaka12138完成签到 ,获得积分10
7秒前
8秒前
FashionBoy应助陌路采纳,获得10
8秒前
田様应助甜甜的冰淇淋采纳,获得10
8秒前
9秒前
粗心的尔曼完成签到,获得积分10
9秒前
量子星尘发布了新的文献求助10
10秒前
10秒前
11秒前
sasa发布了新的文献求助10
11秒前
浮游应助爱喝汽水的boy采纳,获得10
11秒前
CodeCraft应助水煮牛肉火锅采纳,获得10
11秒前
整齐的不评完成签到,获得积分10
11秒前
Ning_完成签到 ,获得积分10
11秒前
倩茹发布了新的文献求助10
12秒前
一夜暴富发布了新的文献求助10
13秒前
14秒前
WUHUIWEN发布了新的文献求助10
15秒前
MITNO1完成签到,获得积分10
16秒前
李健应助沉默的宛筠采纳,获得10
18秒前
19秒前
Kessino发布了新的文献求助10
19秒前
20秒前
22秒前
量子星尘发布了新的文献求助10
22秒前
22秒前
时尚白凡完成签到 ,获得积分10
23秒前
24秒前
tao发布了新的文献求助10
24秒前
小L同学发布了新的文献求助10
24秒前
陌路发布了新的文献求助10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Acute Mountain Sickness 2000
Handbook of Milkfat Fractionation Technology and Application, by Kerry E. Kaylegian and Robert C. Lindsay, AOCS Press, 1995 1000
A novel angiographic index for predicting the efficacy of drug-coated balloons in small vessels 500
Textbook of Neonatal Resuscitation ® 500
The Affinity Designer Manual - Version 2: A Step-by-Step Beginner's Guide 500
Affinity Designer Essentials: A Complete Guide to Vector Art: Your Ultimate Handbook for High-Quality Vector Graphics 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5069424
求助须知:如何正确求助?哪些是违规求助? 4290685
关于积分的说明 13368587
捐赠科研通 4110923
什么是DOI,文献DOI怎么找? 2251090
邀请新用户注册赠送积分活动 1256336
关于科研通互助平台的介绍 1188867